@article{3110160,
    title = "Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma",
    author = "Elaidi, R. and Harbaoui, A. and Beuselinck, B. and Eymard, J.-C. and Bamias, A. and De Guillebon, E. and Porta, C. and Vano, Y. and Linassier, C. and Debruyne, P.R. and Gross-Goupil, M. and Ravaud, A. and Aitelhaj, M. and Marret, G. and Oudard, S.",
    journal = "Annals of Oncology",
    year = "2015",
    volume = "26",
    number = "2",
    pages = "378-385",
    publisher = "Oxford University Press",
    issn = "0923-7534, 1569-8041",
    doi = "10.1093/annonc/mdu552",
    keywords = "axitinib;  everolimus;  pazopanib;  protein tyrosine kinase inhibitor;  sorafenib;  sunitinib;  temsirolimus;  antineoplastic agent;  MTOR protein, human;  protein kinase inhibitor;  protein tyrosine kinase;  target of rapamycin kinase, adult;  aged;  Article;  bone metastasis;  cancer grading;  cancer survival;  cohort analysis;  controlled study;  drug treatment failure;  female;  Fuhrman grade;  human;  kidney carcinoma;  major clinical study;  male;  metastatic clear cell renal cell carcinoma;  metastatic clear cell renal cell carcinoma;  priority journal;  progression free survival;  retrospective study;  time to treatment;  treatment duration;  treatment outcome;  antagonists and inhibitors;  Carcinoma, Renal Cell;  clinical trial;  disease free survival;  Kaplan Meier method;  middle aged;  mortality;  multicenter study;  procedures;  proportional hazards model;  salvage therapy;  treatment outcome, Aged;  Antineoplastic Agents;  Carcinoma, Renal Cell;  Disease-Free Survival;  Female;  Humans;  Kaplan-Meier Estimate;  Male;  Middle Aged;  Proportional Hazards Models;  Protein Kinase Inhibitors;  Protein-Tyrosine Kinases;  Retrospective Studies;  Salvage Therapy;  TOR Serine-Threonine Kinases;  Treatment Outcome",
    abstract = "In a comparison of tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin inhibitor (mTORi) in patients with metastatic clear-cell renal cell carcinoma who received a 1st-line TKI for at least 6 months, the TKI-TKI sequence was favored over the TKI-mTORi. Long-term 2nd-line responders were more likely to have received a second TKI and to have been long-term responders to a 1st-line TKI. © The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved."
}